BAOTOU DONGBAO BIO-TECH CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.93 CNY | +1.02% |
|
-0.40% | -20.87% |
| 24/05 | Baotou Dongbao Bio-Tech Co.,Ltd Announces 2023 Final Cash Distribution Plan on A Shares, Payable on 31 May 2024 | CI |
| 15/05 | Baotou Dongbao Bio-Tech Co.,Ltd Approves Management Appointments | CI |
| Sales 2022 | 943M 130M 10.84B | Sales 2023 | 975M 134M 11.2B | Capitalization | 3.7B 510M 42.51B |
|---|---|---|---|---|---|
| Net income 2022 | 109M 15.02M 1.25B | Net income 2023 | 120M 16.54M 1.38B | EV / Sales 2022 | 4.55 x |
| Net cash position 2022 | 161M 22.19M 1.85B | Net cash position 2023 | 280M 38.59M 3.22B | EV / Sales 2023 | 3.51 x |
| P/E ratio 2022 |
40.7
x | P/E ratio 2023 |
31.8
x | Employees | 1,441 |
| Yield 2022 |
0.35% | Yield 2023 |
0.35% | Free-Float | 60.7% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.02% | ||
| 1 week | -0.40% | ||
| Current month | -2.95% | ||
| 1 month | -7.85% | ||
| 3 months | -3.90% | ||
| 6 months | -19.97% | ||
| Current year | -20.87% |
1 week
4.76
4.96
1 month
4.635.60
Current year
3.636.73
1 year
3.636.80
3 years
3.639.39
5 years
3.639.85
10 years
3.3914.68
| Managers | Title | Age | Since |
|---|---|---|---|
Fang Liu
CEO | Chief Executive Officer | 60 | 10/21/10 |
Haiqing Hao
DFI | Director of Finance/CFO | 48 | 17/19/17 |
Yan Liu
BRD | Director/Board Member | 37 | 10/21/10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ai Guo Wang
CHM | Chairman | 55 | 10/21/10 |
De Bu Gao
BRD | Director/Board Member | 69 | 12/20/12 |
Fang Liu
CEO | Chief Executive Officer | 60 | 10/21/10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 4.93 | +1.02% | 3,678,500 |
| 14/24/14 | 4.88 | +1.88% | 4,206,000 |
| 13/24/13 | 4.79 | -2.44% | 6,143,900 |
| 12/24/12 | 4.91 | 0.00% | 5,974,100 |
End-of-day quote Shenzhen S.E., June 17, 2024
More quotes
Baotou Dongbao Bio-Tech Co., Ltd is principally engaged in the research, development, manufacture and distribution of gelatin series products and low molecular mass collagen. The Company primarily provides gelatin, which is used in the manufacture of empty capsules and food additives; calcium hydrophosphate, which is used in feed additives, as well as collagen series products, which are used in foods, cosmetics, health care products. The Company distributes its products in both domestic and overseas markets, with domestic markets as its major markets.
Sector
Pharmaceuticals
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.87% | 403M | |
| +20.76% | 43.54B | |
| +18.62% | 21.51B | |
| +18.26% | 15.34B | |
| +26.36% | 15.12B | |
| +56.55% | 13.37B | |
| -0.05% | 6.79B | |
| -14.94% | 6.38B | |
| -8.87% | 5.73B | |
| +8.17% | 5.36B |
- Stock Market
- Equities
- 300239 Stock
